User login
Key clinical point: Findings from the CONTROL trial support adding adalimumab over escalating methotrexate in patients with psoriatic arthritis (PsA) who respond inadequately to the initial methotrexate dose.
Major finding: At week 16, a significantly higher proportion of patients achieved minimal disease activity after adding adalimumab to methotrexate vs. escalating methotrexate dose (41% vs. 13%; P < .0001), with the efficacy being maintained through 32 weeks by 80% of adalimumab responders despite methotrexate withdrawal at 16 weeks. No new safety signals were identified.
Study details: Findings are from the phase 4 CONTROL trial including 245 patients with active PsA with an inadequate response to methotrexate. They were randomly assigned to receive 15 mg/week adalimumab+methotrexate or have a methotrexate dose escalated up to 25 mg/week for 16 weeks; responders either maintained or modified their current therapy and nonresponders had their therapy escalated until 32 weeks.
Disclosures: This study was funded by AbbVie. Four authors declared being employees or stockholders of AbbVie and other authors reported ties with various sources including AbbVie.
Source: Coates LC et al. Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study. Lancet Rheumatol. 2022 (Feb 25). Doi: 10.1016/S2665-9913(22)00008-X
Key clinical point: Findings from the CONTROL trial support adding adalimumab over escalating methotrexate in patients with psoriatic arthritis (PsA) who respond inadequately to the initial methotrexate dose.
Major finding: At week 16, a significantly higher proportion of patients achieved minimal disease activity after adding adalimumab to methotrexate vs. escalating methotrexate dose (41% vs. 13%; P < .0001), with the efficacy being maintained through 32 weeks by 80% of adalimumab responders despite methotrexate withdrawal at 16 weeks. No new safety signals were identified.
Study details: Findings are from the phase 4 CONTROL trial including 245 patients with active PsA with an inadequate response to methotrexate. They were randomly assigned to receive 15 mg/week adalimumab+methotrexate or have a methotrexate dose escalated up to 25 mg/week for 16 weeks; responders either maintained or modified their current therapy and nonresponders had their therapy escalated until 32 weeks.
Disclosures: This study was funded by AbbVie. Four authors declared being employees or stockholders of AbbVie and other authors reported ties with various sources including AbbVie.
Source: Coates LC et al. Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study. Lancet Rheumatol. 2022 (Feb 25). Doi: 10.1016/S2665-9913(22)00008-X
Key clinical point: Findings from the CONTROL trial support adding adalimumab over escalating methotrexate in patients with psoriatic arthritis (PsA) who respond inadequately to the initial methotrexate dose.
Major finding: At week 16, a significantly higher proportion of patients achieved minimal disease activity after adding adalimumab to methotrexate vs. escalating methotrexate dose (41% vs. 13%; P < .0001), with the efficacy being maintained through 32 weeks by 80% of adalimumab responders despite methotrexate withdrawal at 16 weeks. No new safety signals were identified.
Study details: Findings are from the phase 4 CONTROL trial including 245 patients with active PsA with an inadequate response to methotrexate. They were randomly assigned to receive 15 mg/week adalimumab+methotrexate or have a methotrexate dose escalated up to 25 mg/week for 16 weeks; responders either maintained or modified their current therapy and nonresponders had their therapy escalated until 32 weeks.
Disclosures: This study was funded by AbbVie. Four authors declared being employees or stockholders of AbbVie and other authors reported ties with various sources including AbbVie.
Source: Coates LC et al. Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study. Lancet Rheumatol. 2022 (Feb 25). Doi: 10.1016/S2665-9913(22)00008-X